Health Condition 1: G328- Other specified degenerative disorders of nervous system in diseases classified elsewhere
Conditions
Interventions
Intervention1: 1 3 1 6 beta glucan therapy: 1 3 1 6 beta glucan will be tested for efficacy and safety in children with DMD for reduction of inflammatory biomarkers like CPK Interleukin 6 and tumor ne
Sponsors
Health N U Therapeutics Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Subject willing to and able to comply with protocol
Exclusion criteria
Exclusion criteria: 1) Patients with a previous (within past 1 month) or concomitant participation in any other therapeutic trial 2) Subjects and legally authorized representative for vulnerable subjects who has not given informed consent 3) Subjects with history of other muscular atrophy disorder 4) Subjects with known or suspected malignancy, any other chronic disease or clinically relevant limitation of renal, liver or heart function according to the discretion of the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in inflammatory markersTimepoint: baseline, 3 months, 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in MRC and NSAA score from baseline at 3 and 6 monthTimepoint: 3 and 6 months | — |
Countries
India
Contacts
Public ContactDr Suvarna Magar
MGM Medical College
Outcome results
None listed